SAB Biotherapeutics’ (SABS) Buy Rating Reaffirmed at HC Wainwright
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 380.00% from the company’s previous close. Separately, Chardan Capital reissued […]
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 380.00% from the company’s previous close. Separately, Chardan Capital reissued […]
